Abstract
EE528 Analysis of Non-Pharmacological Cost Savings Derived from the Use of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection in Patients with HER2-Positive Breast Cancer in Spain
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have